The Journal of Urology
Volume 183, Issue 6 , Pages 2200-2205, June 2010

Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer

  • Philip J. Saylor

      Affiliations

    • Corresponding Author InformationCorrespondence: Division of Hematology-Oncology, Massachusetts General Hospital Cancer Center, 55 Fruit St., Lawrence House/POB-2, Boston, Massachusetts 02114 (telephone: 617-643-1723; FAX: 617-724-3166)
  • ,
  • Donald S. Kaufman
  • ,
  • M. Dror Michaelson
  • ,
  • Richard J. Lee
  • ,
  • Matthew R. Smith

      Affiliations

    • Recipient of a National Institutes of Health K24 Midcareer Investigator Award (5K24CA121990-02) and grants from the Prostate Cancer Foundation.

Division of Hematology-Oncology, Massachusetts General Hospital, Boston, Massachusetts

Received 9 October 2009 published online 16 April 2010.

Purpose

Osteoporosis causes morbidity and mortality in men. The National Osteoporosis Foundation recommends fracture risk assessment with the online WHO/FRAX® tool. Although androgen deprivation therapy for prostate cancer increases fracture risk, there is limited information about which men require preventative drug therapy. We applied the WHO/FRAX tool to men treated with androgen deprivation therapy for prostate cancer.

Materials and Methods

Information was collected from a practice cohort of men treated with gonadotropin-releasing hormone agonists, and included age, height, weight, history of gonadotropin-releasing hormone agonist treatment, dual energy x-ray absorptiometry results, prior bone targeted therapy and clinical risk factors for fracture. Subjects were evaluated with the WHO/FRAX algorithm (http://www.shef.ac.uk/FRAX/).

Results

A total of 363 men treated with androgen deprivation therapy (median age 72 years) were evaluated. By the FRAX algorithm with clinical information (no dual energy x-ray absorptiometry data) the 3% hip fracture risk threshold for treatment was exceeded by 51.2% of the men (median risk 3.1%). When subjects were grouped by age the treatment threshold was reached by 3.3% of those younger than 70 years, 76.6% of those 70 to 79 years old and by 98.8% of those 80 years old or older. Using FRAX with bone mineral density data in the 93 patients who underwent bone mineral density testing the median 10-year hip fracture risk was 0.9% and the treatment threshold was exceeded by 15% of these subjects.

Conclusions

In this cohort of men receiving androgen deprivation therapy the prevalence of risk sufficient to necessitate drug therapy was high and was strongly influenced by age. The WHO/FRAX algorithm identifies a greater proportion of men for treatment than the traditional threshold of T score −2.5 or less.

Key Words: prostatic neoplasms, osteoporosis, fractures, bone, androgens

Abbreviations and Acronyms: ADT, androgen deprivation therapy, BMD, bone mineral density, BMI, body mass index, DXA, dual energy x-ray absorptiometry, GnRH, gonadotropin-releasing hormone, MOF, major osteoporotic fracture, NCCN, National Comprehensive Cancer Network, NOF, National Osteoporosis Foundation

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Study was received institutional review board approval.

 See Editorial on page 2122.

PII: S0022-5347(10)00263-6

doi:10.1016/j.juro.2010.02.022

The Journal of Urology
Volume 183, Issue 6 , Pages 2200-2205, June 2010